Daiwa Securities Group
ABUS icon

Daiwa Securities Group’s Arbutus Biopharma ABUS Stock Holding History

Daiwa Securities Group’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-395
Closed -$2K – 1180
2025
Q4 		$2K Sell
395
-14,100
-97% -$63.4K ﹤0.01% 1295
2025
Q3 		$66K Sell
14,495
-1,349
-9% -$4.96K ﹤0.01% 1070
2025
Q2 		$49K Buy
15,844
+15,449
+3,911% +$51.3K ﹤0.01% 1069
2025
Q1 		$1K Hold
395
– – ﹤0.01% 1207
2024
Q4 		$1K Hold
395
– – ﹤0.01% 1241
2024
Q3 		$2K Hold
395
– – ﹤0.01% 1211
2024
Q2 		$1K Hold
395
– – ﹤0.01% 1276
2024
Q1 		$1K Hold
395
– – ﹤0.01% 1286
2023
Q4 		$1K Hold
395
– – ﹤0.01% 1286
2023
Q3 		$1K Hold
395
– – ﹤0.01% 1233
2023
Q2 		$1K Hold
395
– – ﹤0.01% 1256
2023
Q1 		$1K Hold
395
– – ﹤0.01% 1235
2022
Q4 		$1K Hold
395
– – ﹤0.01% 1252
2022
Q3 		$1K Hold
395
– – ﹤0.01% 1262
2022
Q2 		$1K Hold
395
– – ﹤0.01% 1270
2022
Q1 		$1K Hold
395
– – ﹤0.01% 1286
2021
Q4 		$2K Buy
395
+235
+147% +$913 ﹤0.01% 1268
2021
Q3 		$1K Hold
160
– – ﹤0.01% 1256
2021
Q2 		$0 Hold
160
– – ﹤0.01% 1254
2021
Q1 		$1K Hold
160
– – ﹤0.01% 1177
2020
Q4 		$1K Buy
+160
New +$560 ﹤0.01% 1155
2019
Q4 		– Sell
-304
Closed – – 1197
2019
Q3 		$0 Hold
304
– – ﹤0.01% 1176
2019
Q2 		$1K Hold
304
– – ﹤0.01% 1168
2019
Q1 		$1K Hold
304
– – ﹤0.01% 1154
2018
Q4 		$1K Hold
304
– – ﹤0.01% 1122
2018
Q3 		$3K Hold
304
– – ﹤0.01% 1100
2018
Q2 		$2K Hold
304
– – ﹤0.01% 1133
2018
Q1 		$2K Buy
+304
New +$1.61K ﹤0.01% 1115

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Daiwa Securities Group's ABUS Position: Q1 2026 in Review

Daiwa Securities Group sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 395 shares — an estimated $2K sold.

Daiwa Securities Group first reported a position in ABUS in Q1 2018 and held it in 28 quarters. The position peaked at $66K in Q3 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Daiwa Securities Group reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 395 Arbutus Biopharma shares in Q1 2026, an estimated $2K.
  • Daiwa Securities Group first reported a position in Arbutus Biopharma in Q1 2018 and held it in 28 quarters.
  • Daiwa Securities Group's Arbutus Biopharma position peaked at $66K in Q3 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.